Journal of Leukocyte Biology, Vol 51, Issue 4 343-349, Copyright © 1992 by Society for Leukocyte Biology
JOURNAL ARTICLE |
H Shau, A Kim and SH Golub
Division of Surgical Oncology, UCLA School of Medicine 90024-1782.
Natural killer (NK) and lymphokine-activated killer (LAK) cell cytotoxic functions can be strongly augmented by the iron-carrier protein lactoferrin (LF). LF significantly enhances NK and LAK activities when added at the beginning of NK or LAK cytotoxicity assays. LF is effective in augmenting cytotoxic activities at concentrations as low as 0.75 microgram/ml, and higher concentrations of LF induce greater augmentation of NK and LAK. Iron does not appear to be essential for LF to increase NK and LAK, as depleting iron from LF with the chelator deferoxamine does not affect the capacity of LF to increase cytotoxicity. LF is known to have RNase enzymatic activity, and LF enhancement of NK and LAK can be blocked by RNA. However, LFs from two different sources with over 100-fold difference in RNase activity are equally effective in enhancing NK and LAK. Furthermore, purified non-LF RNase does not modulate NK or LAK activity and DNA is as effective as RNA in blocking LF augmentation of NK or LAK cytotoxicity. Therefore, the RNase activity is unlikely to be responsible for LF enhancement of the cytotoxicities. Newborn infants are known to have low NK activity and NK and LAK cells have been implicated in host defense against microbial infections. Thus, maternal milk-derived LF may have a role in boosting antimicrobial immunity in the early stages of life. In adults, LF released from neutrophils may enhance NK and LAK functions in the inflammatory process induced by microbial infections.
This article has been cited by other articles:
 |
|
 |
|
  Y. Andersson, M.-L. Hammarstrom, B. Lonnerdal, G. Graverholt, H. Falt, and O. Hernell Formula Feeding Skews Immune Cell Composition toward Adaptive Immunity Compared to Breastfeeding J. Immunol., October 1, 2009; 183(7): 4322 - 4328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Spadaro, C. Caorsi, P. Ceruti, A. Varadhachary, G. Forni, F. Pericle, and M. Giovarelli Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells FASEB J, August 1, 2008; 22(8): 2747 - 2757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Spadaro, C. Curcio, A. Varadhachary, F. Cavallo, J. Engelmayer, P. Blezinger, F. Pericle, and G. Forni Requirement for IFN-{gamma}, CD8+ T Lymphocytes, and NKT Cells in Talactoferrin-Induced Inhibition of neu+ Tumors Cancer Res., July 1, 2007; 67(13): 6425 - 6432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Wolf, G. Li, A. Varadhachary, K. Petrak, M. Schneyer, D. Li, J. Ongkasuwan, X. Zhang, R. J. Taylor, S. E. Strome, et al. Oral Lactoferrin Results in T Cell-Dependent Tumor Inhibition of Head and Neck Squamous Cell Carcinoma In vivo Clin. Cancer Res., March 1, 2007; 13(5): 1601 - 1610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-i. Fujita, E. Matsuda, K. Sekine, M. Iigo, and H. Tsuda Lactoferrin enhances Fas expression and apoptosis in the colon mucosa of azoxymethane-treated rats Carcinogenesis, October 1, 2004; 25(10): 1961 - 1966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Takayama, H. Takahashi, K. Mizumachi, and T. Takezawa Low Density Lipoprotein Receptor-related Protein (LRP) Is Required for Lactoferrin-enhanced Collagen Gel Contractile Activity of Human Fibroblasts J. Biol. Chem., June 6, 2003; 278(24): 22112 - 22118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Caccavo, N. M. Pellegrino, M. Altamura, A. Rigon, L. Amati, A. Amoroso, and E. Jirillo Review: Antimicrobial and immunoregulatory functions of lactoferrin and its potential therapeutic application Innate Immunity, December 1, 2002; 8(6): 403 - 417. [Abstract] [PDF]
|
|
|
|
 |
|
 C. M. D'Cruz, S. E. Moody, S. R. Master, J. L. Hartman, E. A. Keiper, M. B. Imielinski, J. D. Cox, J. Y. Wang, S. I. Ha, B. A. Keister, et al. Persistent Parity-Induced Changes in Growth Factors, TGF-{beta}3, and Differentiation in the Rodent Mammary Gland Mol. Endocrinol., September 1, 2002; 16(9): 2034 - 2051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Edde, R. B. Hipolito, F. F. Y. Hwang, D. R. Headon, R. A. Shalwitz, and M. P. Sherman Lactoferrin protects neonatal rats from gut-related systemic infection Am J Physiol Gastrointest Liver Physiol, November 1, 2001; 281(5): G1140 - G1150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Caccavo, A. Afeltra, S. Pece, G. Giuliani, M. Freudenberg, C. Galanos, and E. Jirillo Lactoferrin-Lipid A-Lipopolysaccharide Interaction: Inhibition by Anti-Human Lactoferrin Monoclonal Antibody AGM 10.14 Infect. Immun., September 1, 1999; 67(9): 4668 - 4672. [Abstract] [Full Text] [PDF]
|
|
